These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16144934)

  • 1. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers.
    Jazaeri AA; Awtrey CS; Chandramouli GV; Chuang YE; Khan J; Sotiriou C; Aprelikova O; Yee CJ; Zorn KK; Birrer MJ; Barrett JC; Boyd J
    Clin Cancer Res; 2005 Sep; 11(17):6300-10. PubMed ID: 16144934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
    Hartmann LC; Lu KH; Linette GP; Cliby WA; Kalli KR; Gershenson D; Bast RC; Stec J; Iartchouk N; Smith DI; Ross JS; Hoersch S; Shridhar V; Lillie J; Kaufmann SH; Clark EA; Damokosh AI
    Clin Cancer Res; 2005 Mar; 11(6):2149-55. PubMed ID: 15788660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
    Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET
    J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique gene expression profile based on pathologic response in epithelial ovarian cancer.
    Spentzos D; Levine DA; Kolia S; Otu H; Boyd J; Libermann TA; Cannistra SA
    J Clin Oncol; 2005 Nov; 23(31):7911-8. PubMed ID: 16204010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
    Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
    Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
    Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
    Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.
    Pamuła-Piłat J; Rubel T; Rzepecka IK; Olbryt M; Herok R; Dansonka-Mieszkowska A; Grzybowska E; Kupryjańczyk J
    J Biol Regul Homeost Agents; 2014; 28(4):659-74. PubMed ID: 25620176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
    Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
    Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
    Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
    Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary.
    Guirguis A; Elishaev E; Oh SH; Tseng GC; Zorn K; DeLoia JA
    Gynecol Oncol; 2008 Feb; 108(2):370-6. PubMed ID: 18083218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
    Marquez RT; Baggerly KA; Patterson AP; Liu J; Broaddus R; Frumovitz M; Atkinson EN; Smith DI; Hartmann L; Fishman D; Berchuck A; Whitaker R; Gershenson DM; Mills GB; Bast RC; Lu KH
    Clin Cancer Res; 2005 Sep; 11(17):6116-26. PubMed ID: 16144910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between Molecular Genetic Markers of DNA Repair and Cell Cycle Control Genes and Response to Platinum-Based Chemotherapy in Ovarian Cancer Patients.
    Zavarikina TM; Khokhlova SV; Tyulyandina AS; Khabas GN; Asaturova AV; Nosova YV; Brenner PK; Kapralova MA; Khodirev DS; Stenina MB
    Bull Exp Biol Med; 2021 Oct; 171(6):755-759. PubMed ID: 34709513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
    Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
    Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer.
    Choi J; Topouza DG; Tarnouskaya A; Nesdoly S; Koti M; Duan QL
    BMC Cancer; 2020 May; 20(1):413. PubMed ID: 32404140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.
    Osterberg L; Levan K; Partheen K; Delle U; Olsson B; Sundfeldt K; Horvath G
    BMC Cancer; 2009 Oct; 9():368. PubMed ID: 19835627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis of gene expression profiles among 3 epithelial ovarian tumor subtypes using cDNA and tissue microarrays].
    Zheng M; Simon R; Kononen J; Sauter G; Mihatsch MJ; Moch H
    Ai Zheng; 2004 Jul; 23(7):771-6. PubMed ID: 15248910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.